Elevet+ Tilmicosin 300 mg/mL Injection for Cattle Australië - Engels - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elevet+ tilmicosin 300 mg/ml injection for cattle

avet health limited - tilmicosin - parenteral liquid/solution/suspension - tilmicosin antibiotic active 300.0 mg/ml - antibiotic & related

BAYTRIL INJECTION SOLUTION Canada - Engels - Health Canada

baytril injection solution

elanco canada limited - enrofloxacin - solution - 50mg - enrofloxacin 50mg - dogs

Pfizer Select marbofloxacin 20 mg/ml Duitsland - Engels - HMA (Heads of Medicines Agencies)

pfizer select marbofloxacin 20 mg/ml

miklich laboratorios s.l - marbofloxacin 20 mg/ml - solution for injection - cattle, pigs - marbofloxacin

Quiflor 20 mg/ml solution Duitsland - Engels - HMA (Heads of Medicines Agencies)

quiflor 20 mg/ml solution

miklich laboratorios s.l - marbofloxacin 20 mg/ml - solution for injection - cattle, pigs - marbofloxacin

Quiflor 100 mg/ml solution Duitsland - Engels - HMA (Heads of Medicines Agencies)

quiflor 100 mg/ml solution

miklich laboratorios s.l - marbofloxacin 100 mg/ml - solution for injection - cattle, pigs females - marbofloxacin

REBIF- interferon beta-1a kit REBIF REBIDOSE- interferon beta-1a kit REBIF- interferon beta-1a injection, solution REBIF- in Verenigde Staten - Engels - NLM (National Library of Medicine)

rebif- interferon beta-1a kit rebif rebidose- interferon beta-1a kit rebif- interferon beta-1a injection, solution rebif- in

emd serono, inc. - interferon beta-1a (unii: xro4566q4r) (interferon beta-1a - unii:xro4566q4r) - interferon beta-1a 8.8 ug in 0.2 ml - rebif is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. rebif is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation. risk summary data from a large population-based cohort study, as well as other published studies over several decades, have not identified a drug-associated risk of major birth defects with the use of interferon beta during early pregnancy. findings regarding a potential risk for low birth weight or miscarriage with the use of interferon beta in pregnancy have been inconsistent (see data) . it is unclear whether, as a class of products, administration of interferon beta therapies to pregnant animals at doses greater than those used clinically results in an increased rate of abortion. the potential for rebif to have adverse effects on em

Myozyme Powder for Solution for Injection Maleisië - Engels - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

myozyme powder for solution for injection

sanofi-aventis (malaysia) sdn. bhd. - rhgaa (alglucosidase alfa) -

Oncaspar Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

oncaspar

servier laboratories nz ltd - pegaspargase 3750 u (4050u including overage) - powder for injection - 3750 u/5ml - active: pegaspargase 3750 u (4050u including overage) excipient: dibasic sodium phosphate hydrochloric acid monobasic sodium phosphate sodium chloride sodium hydroxide sucrose - oncaspar is indicated as a component of antineoplastic combination therapy in patients with acute lymphoblastic leukaemia (all).

Marbocyl 2%W/V Solution For Injection Maleisië - Engels - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

marbocyl 2%w/v solution for injection

gladron chemicals sdn bhd - marbofloxacin -

SYLVANT- siltuximab injection, powder, lyophilized, for solution Verenigde Staten - Engels - NLM (National Library of Medicine)

sylvant- siltuximab injection, powder, lyophilized, for solution

janssen biotech, inc. - siltuximab (unii: t4h8fma7im) (siltuximab - unii:t4h8fma7im) - siltuximab 100 mg - sylvant is indicated for the treatment of patients with multicentric castleman's disease (mcd) who are human immunodeficiency virus (hiv) negative and human herpesvirus-8 (hhv-8) negative. limitations of use sylvant was not studied in patients with mcd who are hiv positive or hhv-8 positive because sylvant did not bind to virally produced il-6 in a nonclinical study. severe hypersensitivity reaction to siltuximab or any of the excipients in sylvant [see warnings and precautions (5.3)] . hypersensitivity reactions, including anaphylactic reaction, hypersensitivity, and drug hypersensitivity have been reported in patients treated with siltuximab. pregnancy category c risk-summary there are no adequate or well-controlled studies in pregnant women. in animal reproduction studies, administration of a human antibody to il-6 to pregnant cynomolgus monkeys caused decreases in globulin levels in pregnant animals and in the offspring. siltuximab crossed the placenta in monkeys. infants born to pregnant women treated wi